We examined 159 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. The subjects were divided in three groups; 90 patients with thrombotic thrombocytopenic purpura, 51 patients with verotoxin-induced hemolytic uremic syndrome, and 18 patients with drug-induced hemolytic uremic syndrome. Eighty-two percent of the patients with thrombotic thrombocytopenic purpura had associated neurological disorders and 78% of druginduced hemolytic uremic syndrome associated with pulmonary edema. Renal insufficiency was noted in the 69% cases with both hemolytic uremic syndrome groups. Seventeen patients with thrombotic thrombocytopenic purpura had systemic lupus erythematosus and 6 were pregnant. Autoantibody were positive in 53% of thrombotic thrombocytopenic purpura. Seventy-seven percent of patients with thrombotic thrombocytope-nic purpura received plasma exchange at 4,000 mL/day three times a week, 71 % antithrombotic agents, and 78% steroid administration, respectively. However, 27% of the patients with hemolytic uremic syndrome were treated by hemodialysis in addition to antithrombotic agents. When drug-induced hemolytic uremic syndrome was diagnosed, the drug was immediately discontinued and the patients were treated with antiplatelet agents. Seventy-four percent of the patients with thrombotic thrombocytopenic purpura were alive at 26 weeks compared with 95% of those with hemolytic uremic syndrome. As thrombotic thrombocytopenic purpura had a high mortality rate in Japan, we should carry out early diagnosis and early treatment.
Summary:
We examined 159 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. The subjects were divided in three groups; 90 patients with thrombotic thrombocytopenic purpura, 51 patients with verotoxin-induced hemolytic uremic syndrome, and 18 patients with drug-induced hemolytic uremic syndrome. Eighty-two percent of the patients with thrombotic thrombocytopenic purpura had associated neurological disorders and 78% of druginduced hemolytic uremic syndrome associated with pulmonary edema. Renal insufficiency was noted in the 69% cases with both hemolytic uremic syndrome groups. Seventeen patients with thrombotic thrombocytopenic purpura had systemic lupus erythematosus and 6 were pregnant. Autoantibody were positive in 53% of thrombotic thrombocytopenic purpura. Seventy-seven percent of patients with thrombotic thrombocytope-nic purpura received plasma exchange at 4,000 mL/day three times a week, 71 % antithrombotic agents, and 78% steroid administration, respectively. However, 27% of the patients with hemolytic uremic syndrome were treated by hemodialysis in addition to antithrombotic agents. When drug-induced hemolytic uremic syndrome was diagnosed, the drug was immediately discontinued and the patients were treated with antiplatelet agents. Seventy-four percent of the patients with thrombotic thrombocytopenic purpura were alive at 26 weeks compared with 95% of those with hemolytic uremic syndrome. As thrombotic thrombocytopenic purpura had a high mortality rate in Japan, we should carry out early diagnosis and early treatment. Key Words: TTP&mdash;Verotoxin-induced HUS&mdash;Drug&mdash;induced HUS&mdash;Plasma exchange. Thrombotic thrombocytopenic purpura (TTP) is a syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, neurological symptoms, and renal dysfunction (1, 2) . Thrombotic thrombocytopenic purpura was initially described by Moschcowitz in 1924 (3) . Years later a similar disease was recognized in young children and designated the hemolytic uremic syndrome (HUS) by Gasser et al. (4) . Thrombotic thrombocytopenic purpura and HUS have the same fundamental pathologic lesion, thrombotic microangiopathy, which is induced by many possible causes of which all initially induce endothelial damage (5, 6) . Some authors believe they should be considered a single condition and be termed TTP/HUS (7, 8) . However, it was recently found that almost all cases of HUS in children are caused by verotoxin (9, 10) . The cause of TTP is still not clear. Toxic responses to mitomycin C, which have been documented since 1979, consist of microangiopathic hemo-lytic anemia, thrombocytopenia, and renal insufficiency (drug-induced HUS) ( 11, 12) . In this study, we evaluated the clinical results, therapeutic effects, and mortality in 159 patients with TTP/HUS in Japan.
PATIENTS
We examined 159 patients with TTP/HUS admitted to many hospitals in Japan for 13 years. The subjects were divided in three groups; 90 patients with TTP, 51 patients with verotoxin-induced HUS, and 18 patients with druginduced HUS. The mean age of TTP (44 ± 18 years old) and drug-induced HUS (58 ± 12 years old) was higher than that of verotoxin-induced HUS ( 11 ± 14 years old). The incidence of TTP was high in women and the incidence of drug-induce HUS was high in males (Table 1) . Seventeen patients were treated with >50 mg/body mitomycin C as well as 5-fluorouracil and adriamycin after a curative operation.
CLINICAL SYMPTOMS AND LABORATORY DATA
The clinical symptoms of TTP and HUS patients are shown in Table 1 . Fever occurred in almost all patients in the three groups. Eighty-two percent of patients with TTP had associated neurological disorders and 78% of patients with drug-induced HUS had associated pulmonary edema. Renal insufficiently was noted in 69% of patients with verotoxin-induced HUS. The common cold was observed in several cases with TTP and verotoxininduced HUS as prodrome. Laboratory data are shown in Table 2 . Serum levels of blood urea nitrogen (BUN) and creatinine were elevated in only 50% of TTP patients, although microscopic hematuria and proteinuria were observed more frequently.
There were no significant differences between laboratory parameters on admission and outcome in TTP and drug-induced HUS. Two cases of verotoxin-induced HUS with severe leukocytosis died on admission. Autoantibodies such as anti-ANA or anti-DNA antibody were positive in 53% of TTP patients, and platelet-associated immunoglobulin G was increased in 78% of TTP patients. Most patients with TTP and HUS had a normal activated partial thromboplastin time (aPTT), prothrombin time (PT), and fibrinogen level, but moderately high fibrinogen and fibrin degradation products (FDP). On von Willebrand factor, high-molecular weight multimer were reduced in almost all cases with TTP. i RESULTS Seventy-seven percent of patients with TTP received plasma exchange (PE) at 4,000 mL/day 3 times a week, 71 % antithrombotic agents (aspirin 300 mg/day), and 78% steroids (methylprednisolone 1,000 mg/day x 3 days) administration, respectively. Ten percent of the patients with TTP responded to corticosteroid alone, without PE. Twenty-seven percent of patients with verotoxin-induced HUS were treated with hemodialysis in addition to heparin and antithrombotic agents. When HUS was diagnosed in the patients with drug-induced HUS, mitomycin C was immediately discontinued and the patients were treated with antiplatelet agents. Complete remission was observed in 70% patients with TTP. Plasma exchange was effective in most patients with TTP with good response. However, recurrence was observed in some patients with TTP, and in these patients large doses of methylprednisolone were required. Seventy-four percent of the patients with TTP were alive at 26 weeks compared with 95% of those with HUS and almost all TTP patients with poor outcome died within 10 weeks (Fig. 1 ). The mortality rate with TTP (27%) was highest among TTP, verotoxin-induced HUS, druginduced HUS (Table 3 ).
DISCUSSION
The outcome of TTP has improved. The survival rate (10%) of TTP patients from 1925 to 1962 was significantly lower than that (46%) from 1964 to 1980 (13) . Antiplatelet therapy plays an important role in the improvement of the survival rate of TTP from 1964 to 1980. The cause of TTP is not clear and is suspected to be of multiple factors. Microthrombi, abnormalities of von Willebrand factor, and platelet aggregating factor are frequently observed in TTP patients (14) . Plasma exchange in TTP was first reported by Rubinstein et al. (15) , and PE has been established since the report of Bukowski et al. (16) . From 1982 to 1987, the efficacy of PE was 165 (80%) of 207 patients. The efficacy of plasma infusion was compared with PE by the Canadian Apheresis Study Group in 1991 (17) . In our study, 77% of patients with TTP received PE, 71 % antithrombotic agents, and 78% steroid administration, respectively. Not all patients with TTP were treated with PE because some patients could not be diagnosed early, their clinical course was very rapid, or their condition was high risk. Seventy-four percent of our patients with TTP were alive at 26 weeks. That slightly low efficacy might be due to insufficient treatment. The delayed diagnosis of TTP did not allow PE or antiplatelet therapy. The different incidence of clinical symptoms including neurological disorder, pulmonary edema, and renal insufficiency in the three TTP/HUS groups may define the different causes of onset. Autoantibodies were positive in 53% of the TTP patients and 17 of 99 of our TTP patients had SLE.
These results suggest that the abnormalities of the immune system may affect the onset of TTP. As many receptors for verotoxin exist in cerebral or renal vascular endothelial cells (18) , these organ failures appear in verotoxin-induced HUS. Increased plasma cytokine levels in the TTP patients (5) may be one of the causes for the onset of TTP. However, only 27% of the patients with HUS were treated by hemodialysis in addition to antithrombotic agents and 77% of the TTP patients received PE. There are different symptoms, treatments, or outcomes among the three groups, suggesting that the causes of these diseases should be different, however, microangiopathic hemolytic anemia and thrombocytopenia are common symptoms. With seven exceptions, almost all patient with TTP died within 10 weeks caused by persistent or progressive disease. Overall survival in TTP was lower than that in HUS. As TTP still has a high mortality rate in Japan, we should carry out early diagnosis and early treatment.
